ABBOTT-OLANZAPINE ODT TABLET (ORALLY DISINTEGRATING)

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

OLANZAPINE

可用日期:

ABBOTT LABORATORIES, LIMITED

ATC代码:

N05AH03

INN（国际名称）:

OLANZAPINE

剂量:

10MG

药物剂型:

TABLET (ORALLY DISINTEGRATING)

组成:

OLANZAPINE 10MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Prescription

治疗领域:

ATYPICAL ANTIPSYCHOTICS

產品總結:

Active ingredient group (AIG) number: 0128783002; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2015-12-31

产品特点

_ _
_Abbott-Olanzapine ODT Product Monograph _
_Page 1 of 62 _
PRODUCT MONOGRAPH
PR
ABBOTT-OLANZAPINE ODT
Olanzapine Orally Disintegrating Tablets
5 mg, 10 mg, 15 mg, 20 mg
Antipsychotic Agent
BGP Pharma Inc.
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Preparation:
January 6, 2015
Submission Control No.: 180719
_ _
_Abbott-Olanzapine ODT Product Monograph _
_Page 2 of 62 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................27
DOSAGE AND ADMINISTRATION
..............................................................................29
OVERDOSAGE
................................................................................................................31
ACTION AND CLINICAL PHARMACOLOGY
............................................................31
STORAGE AND STABILITY
..........................................................................................34
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................34
PART II: SCIENTIFIC INFORMATION
...............................................................................35
PHARMACEUTICAL INFORMATION
..........................................................................35
CLINICAL TRIALS
............................................................................................